Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
KNSA - Kiniksa Pharmaceuticals International, plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$70.80
DETAILS
HIGH:
$75.00
LOW:
$62.00
MEDIAN:
$72.00
CONSENSUS:
$70.80
DOWNSIDE:
10.88%
Stock News
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis treatment.
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.23 per share a year ago.
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 – – KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients – – Conference call and webcast scheduled for 8:30 am ET today –
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
- ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243. 6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 -- KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients -- Conference call and webcast scheduled for 8:30 am ET today - LONDON, July 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported second quarter 2026 financial results and recent portfolio execution.
5 Stocks With Recent Price Strength Despite Recent Market Volatility
Despite a volatile market, AOUT, CMPR, NESR, CTO and KNSA are five stocks showing recent price strength.
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
Let's take a look at four stocks, FLXS, ARKO, KNSA and BSET, with impressive net profit margins for a robust portfolio.
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Grab These 4 Stocks With Solid Net Profit Margins to Maximize Returns
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued After 3.5% Rally? GF Value Says Overvalued
On June 22, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares rose 3.5% today, bringing the current price to $57.13. The stock has shown strong perf
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
New Strong Buy Stocks for June 18th
TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 2026.
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41
On May 29, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares fell 4.8% to $48.41, reflecting a downward trend in the stock's performance over the pa
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in June:
Price Targets
Kiniksa price target raised to $75 from $60 at Goldman Sachs
$75.00
(was $62.44)
Paul Choi
·
Goldman Sachs
Kiniksa price target raised to $74 from $57 at Wells Fargo
$74.00
(was $63.44)
Wells Fargo
Kiniksa price target raised to $72 from $59 at Wedbush
$72.00
(was $59.20)
Wedbush
Kiniksa price target raised to $59 from $58 at Wedbush
$59.00
(was $53.85)
Wedbush
Kiniksa price target raised to $71 from $58 at Jefferies
$71.00
(was $53.80)
Roger Song
·
Jefferies
Kiniksa price target raised to $58 from $53 at Wedbush
$58.00
(was $46.25)
Wedbush
Kiniksa initiated with a Buy at Canaccord
$62.00
(was $45.39)
Canaccord Genuity
Kiniksa price target raised to $50 from $48 at Wedbush
$50.00
(was $39.65)
David Nierengarten
·
Wedbush
Kiniksa price target raised to $55 from $45 at Goldman Sachs
$55.00
(was $37.81)
Goldman Sachs
Kiniksa price target raised to $44 from $38 at Wedbush
$44.00
(was $37.89)
Wedbush
Kiniksa price target raised to $54 from $45 at Jefferies
$54.00
(was $30.37)
Jefferies
Kiniksa (KNSA) PT Raised to $35 at Evercore ISI
$35.00
(was $23.27)
Liisa Bayko
·
Evercore ISI
Jefferies Starts Kiniksa (KNSA) at Buy
$40.00
(was $24.49)
Roger Song
·
Jefferies
Wells Fargo Starts Kiniksa (KNSA) at Overweight, 'we see +15-25% upside potential'
$34.00
(was $19.38)
Eva Fortea Verdejo
·
Wells Fargo